News

The FDA has granted Priority Review of the NDA and assigned a Prescription Drug User Fee Act (PDUFA) target action date of March 19, 2020. The submission was

The Dapagliflozin and prevention of adverse-outcomes in heart failure (DAPA-HF) study demonstrated Farxiga’s potential with a statistically-significant and clinically-meaningful reduction of cardiovascular death or the declining of heart

Recruitment in the trial is underway and the first patient has been enrolled. The Company anticipates reporting top-line data from this trial in the second half of 2020.

At present, the mRNA-1893 vaccine is being assessed in a phase 1 study to prevent Zika virus infection in healthy adults. The mRNA-1893 included an mRNA sequence that

Under the terms of the agreement, Siamab will receive a multimillion-dollar initial payment and is eligible to receive additional payments when specific milestones are achieved. No additional terms

The investment secured by Sanfer is expected to help the company implement its continued expansion plans in Mexico and in other parts of Latin America. Additional terms of

Rearranged during transfection (RET) is a receptor tyrosine kinase that activates multiple downstream pathways involved in cell proliferation and survival. RET fusions are implicated in several cancers including

RINVOQ is expected to be available in the U.S. in late August 2019. The FDA approval of RINVOQ is supported by data from the SELECT program, one of

Inrebic is an oral kinase inhibitor with activity against wild type and mutationally activated Janus Associated Kinase 2 (JAK2) and FMS-like tyrosine kinase 3 (FLT3). It is a